What Should You know About Adicet Bio (ACET) Before Investing?

By Blake Campbell • Thursday, May 18 15:01 • Permanent Link

Adicet Bio moved -6.5% this afternoon session, trading between a high of $6.71 and a low of $6.195 per share. Yesterday the stock finished at $6.67 per share, compared to an average analyst target price of $26.75.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The small-cap biotechnology: pharmaceutical preparations company is based in the United States. Adicet Bio has trailing twelve months earnings per share (EPS) of -2.66, which at today's prices amounts to a price to earnings (P/E) ratio of -2.3.

Snapshot of Adicet Bio's Operating Margins:

Date Reported	Total Revenue ($ k)	Operating Expenses ($ k)	Operating Margins (%)	YoY Growth (%)
2022-12-31	24,990	97,541	-290.32	54.02
2021-12-31	9,730	71,163	-631.38	-188.42
2020-12-31	17,903	57,094	-218.91	93.06
2019-12-31	995	32,383	-3154.57	n/a

Averaging out to -1073.8% over the last 4 years, Adicet Bio's operating margins also have a high coefficient of variability, which stands at 130.3%. On the other hand, we note that the firm's margins are growing at a 44.9% compounded average yearly rate.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.